Opdivo

Male and female superheroes posing in fluttering cloaks
Biotech

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

IO Biotech's cancer vaccine, in combination with Keytruda, delivered an objective response rate of 44.4%, hitting the study's primary endpoint.
Darren Incorvaia Sep 14, 2024 2:30am
A histology stain of pancreatic ductal adenocarcinoma

ASCO: Early Purple Biotech data shows gains in pancreatic cancer

Jun 1, 2024 8:00am
BMS

BMS plans $1.5B in cuts through '25, with 2,000-plus layoffs

Apr 25, 2024 8:40am
pay deal hand over cash licensing transaction money

Ono taps Shattuck for $227M bifunctional fusion protein deal

Feb 13, 2024 8:29am
success failure signposts

Ultimovacs links BMS-cancer vaccine combo to improved survival

Oct 18, 2023 8:40am
slow economic growth

Long survival spurs Ultimovacs to mull ways to end cancer trial

Aug 22, 2023 10:00am